Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00099216 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

A Phase 3 study of Vascular Dementia, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
708
Enrollment target
20
Study locations

NCT00099216 is a Phase 3 study of Vascular Dementia that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 708 participants, below the 1,127-participant average among 10 other Vascular Dementia trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00099216, a Phase 3 study of Vascular Dementia, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
708 participants
Enrollment target
20
Study locations

Study Summary

The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Conditions Studied

Vascular Dementia

Interventions

  • DRUG Rivastigmine

Study Locations (20)

Florida

  • - Boynton Beach
  • - Miami Beach
  • - Port Charlotte

Other

  • - Graz
  • - Linz
  • - Vienna

California

  • - Irvine
  • - San Francisco

Pennsylvania

  • - Allentown
  • - Greensburg

Texas

  • - Austin
  • - Houston

Indiana

  • - Indianapolis

Iowa

  • - Des Moines

Missouri

  • - St Louis

Trial Details

FieldValue
Enrollment Target 708 participants
Start Date 2001-08
Est. Completion 2005-11
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00099216

The ClinicalTrials.gov registry entry for NCT00099216 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 708 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,127-participant average among 10 other Vascular Dementia trials with a reported enrollment target (37% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Vascular Dementia appearing as the primary indexed condition, and to 1 intervention - of which Rivastigmine is the first listed.

NCT00099216 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Other, California.

Frequently Asked Questions

What is clinical trial NCT00099216 about?

NCT00099216 is a clinical study titled "Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia". The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

What is the current status of trial NCT00099216?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 708 participants. The study started on 2001-08. Estimated completion is 2005-11.

What conditions does trial NCT00099216 study?

This clinical trial studies the following conditions: Vascular Dementia.

What interventions are being tested in trial NCT00099216?

The interventions under investigation include: Rivastigmine (DRUG).

Who is sponsoring clinical trial NCT00099216?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00099216 being conducted?

This trial has 20 study locations across California, Florida, Indiana, Iowa, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Vascular Dementia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Vascular Dementia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.